Skip to main content

Table 2 KEGG pathway analysis of aberrantly methylated-differentially expressed genes in hepatocellular carcinoma

From: DNA methylation biomarkers for hepatocellular carcinoma

Pathway ID Pathway name Gene count False discovery rate Genes
Hypomethylation and high expression
 4110 Cell cycle 12 1.03E−15 ANAPC10, ANAPC4, BUB1, BUB1B, BUB3, CCNB1, CDC16, CDC20, CDC23, MAD1L1, MAD2L1, PTTG1
 4114 Oocyte meiosis 10 6.60E−13 ANAPC10, ANAPC4, AURKA, BUB1, CCNB1, CDC16, CDC20, CDC23, MAD2L1, PTTG1
 4914 Progesterone-mediated oocyte maturation 8 1.84E−10 ANAPC10, ANAPC4, BUB1, CCNB1, CDC16, CDC23, MAD1L1, MAD2L1
 4120 Ubiquitin mediated proteolysis 6 1.11E−05 ANAPC10, ANAPC4, CDC16, CDC20, CDC23, DDB1
 4360 Axon guidance 4 0.00416 ROBO1, SLIT1, SLIT2, SLIT3
Hypermethylation and low expression
 5200 Pathways in cancer 9 3.99E−07 AR, CCND1, CDK4, CDK6, CDKN1A, HHIP, NTRK1, PTCH1, SHH
 4115 p53 signaling pathway 4 0.000145 CCND1, CDK4, CDK6, CDKN1A
 4110 Cell cycle 4 0.00109 CCND1, CDK4, CDK6, CDKN1A
 4010 MAPK signaling pathway 5 0.00115 BDNF, NGF, NTF4, NTRK1, NTRK2
 5205 Proteoglycans in cancer 4 0.00503 CCND1, CDKN1A, ESR1, PTCH1